Role of regulatory T cells in experimental arthritis and implications for clinical use 英文参考文献.docVIP

Arthritis Research Therapy June 2005 Vol 7 No 3 Londei Commentary Role of regulatory T cells in experimental arthritis and implications for clinical use Marco Londei Institute of Child Health, University College London, London, UK Corresponding author: Marco Londei, m.londei@ich.ucl.ac.uk Published: 7 April 2005 Arthritis Research Therapy 2005, 7:118-120 (DOI 10.1186/ar1745) This article is online at /content/7/3/118 ? 2005 BioMed Central Ltd See related research by Frey et al. in issue 7.2, page 90, /content/7/2/R291 Abstract during the induction phase of autoimmunity has also been previously confirmed in collagen-induced arthritis [6], one of the most widely used RA animal models [7]. CD4+ CD25+ T regulatory cells are avidly studied because they modulate immune responses. Their possible role in autoimmunity and more specifically in rheumatoid arthritis (RA) has been highlighted by a string of reports, one of which is in the last issue of Arthritis Research Therapy. There are, however, key questions that have not yet been addressed before their use can be considered as a real therapeutic option. The first is the actual, in a clinical setting, efficacy of Treg to treat active chronic autoimmune diseases such as RA. The second is how we can practically deliver their therapeutic activity in patients. Once these points have been addressed we will have a new and potentially very effective ‘magic bullet’ for the treatment of chronic autoimmune diseases. Frey and colleagues [1] show that CD4+CD25+ Treg also have a fundamental role in the experimental antigen-induced arthritis. However, not all RA animal models seem to respond to CD4+CD25+ Treg manipulation as described in proteo- glycan-induced arthritis [8]. On this backdrop the paper by Frey and colleagues represents only a minor blink of an eye in the vast Treg literature, but Frey and colleagues introduce a provo